Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3 - PubMed (original) (raw)
Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3
Yolande Chvatchko et al. J Immunol. 2003.
Abstract
Chemokines play a key role in the recruitment of activated CD4(+) T cells and eosinophils into the lungs in animal models of airway inflammation. Inhibition of inflammation by N-terminally modified chemokines is well-documented in several models but is often reported with limited dose regimens. We have evaluated the effects of doses ranging from 10 ng to 100 micro g of two CC chemokine receptor antagonists, Met-RANTES/CC chemokine ligand 5 (CCL5) and aminooxypentane-RANTES/CCL5, in preventing inflammation in the OVA-sensitized murine model of human asthma. In the human system, aminooxypentane-RANTES/CCL5 is a full agonist of CCR5, but in the murine system neither variant is able to induce cellular recruitment. Both antagonists showed an inverse bell-shaped inhibition of cellular infiltration into the airways and mucus production in the lungs following allergen provocation. The loss of inhibition at higher doses did not appear to be due to partial agonist activity because neither variant showed activity in recruiting cells into the peritoneal cavity at these doses. Surprisingly, neither was able to bind to the major CCR expressed on eosinophils, CCR3. However, significant inhibition of eosinophil recruitment was observed. Both analogues retained high affinity binding for murine CCR1 and murine CCR5. Their ability to antagonize CCR1 and CCR5 but not CCR3 was confirmed by their ability to prevent RANTES/CCL5 and macrophage inflammatory protein-1beta/CCL4 recruitment in vitro and in vivo, while they had no effect on that induced by eotaxin/CCL11. These results suggest that CCR1 and/or CCR5 may be potential targets for asthma therapy.
Similar articles
- Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors.
Proudfoot AE, Buser R, Borlat F, Alouani S, Soler D, Offord RE, Schröder JM, Power CA, Wells TN. Proudfoot AE, et al. J Biol Chem. 1999 Nov 5;274(45):32478-85. doi: 10.1074/jbc.274.45.32478. J Biol Chem. 1999. PMID: 10542293 - Aminooxypentane-RANTES induces CCR3 activation and internalization of CCR3 from the surface of human eosinophils.
Elsner J, Dulkys Y, Kimmig D, Wells TN, Proudfoot AE, Kapp A. Elsner J, et al. Int Arch Allergy Immunol. 2001 Jan-Mar;124(1-3):227-9. doi: 10.1159/000053719. Int Arch Allergy Immunol. 2001. PMID: 11306977 - Differential activation of CC chemokine receptors by AOP-RANTES.
Elsner J, Mack M, Brühl H, Dulkys Y, Kimmig D, Simmons G, Clapham PR, Schlöndorff D, Kapp A, Wells TN, Proudfoot AE. Elsner J, et al. J Biol Chem. 2000 Mar 17;275(11):7787-94. doi: 10.1074/jbc.275.11.7787. J Biol Chem. 2000. PMID: 10713092 - CC-chemokine receptors in chronic obstructive pulmonary disease.
Bracke KR, Demedts IK, Joos GF, Brusselle GG. Bracke KR, et al. Inflamm Allergy Drug Targets. 2007 Jun;6(2):75-9. doi: 10.2174/187152807780832292. Inflamm Allergy Drug Targets. 2007. PMID: 17692030 Review. - Targeting CCL5 in inflammation.
Marques RE, Guabiraba R, Russo RC, Teixeira MM. Marques RE, et al. Expert Opin Ther Targets. 2013 Dec;17(12):1439-60. doi: 10.1517/14728222.2013.837886. Epub 2013 Oct 3. Expert Opin Ther Targets. 2013. PMID: 24090198 Free PMC article. Review.
Cited by
- Co-Stimulation with TWEAK and TGF-β1 Induces Steroid-Insensitive TSLP and CCL5 Production in BEAS-2B Human Bronchial Epithelial Cells.
Abe S, Harada N, Sandhu Y, Sasano H, Tanabe Y, Ueda S, Nishimaki T, Sato Y, Takeshige T, Harada S, Akiba H, Takahashi K. Abe S, et al. Int J Mol Sci. 2024 Oct 29;25(21):11625. doi: 10.3390/ijms252111625. Int J Mol Sci. 2024. PMID: 39519176 Free PMC article. - CCL5 is a potential bridge between type 1 and type 2 inflammation in asthma.
Gauthier M, Kale SL, Oriss TB, Gorry M, Ramonell RP, Dalton K, Ray P, Fahy JV, Seibold MA, Castro M, Jarjour N, Gaston B, Bleecker ER, Meyers DA, Moore W, Hastie AT, Israel E, Levy BD, Mauger D, Erzurum S, Comhair SA, Wenzel SE, Ray A. Gauthier M, et al. J Allergy Clin Immunol. 2023 Jul;152(1):94-106.e12. doi: 10.1016/j.jaci.2023.02.028. Epub 2023 Mar 8. J Allergy Clin Immunol. 2023. PMID: 36893862 Free PMC article. - New drugs targeting Th2 lymphocytes in asthma.
Caramori G, Groneberg D, Ito K, Casolari P, Adcock IM, Papi A. Caramori G, et al. J Occup Med Toxicol. 2008 Feb 27;3 Suppl 1(Suppl 1):S6. doi: 10.1186/1745-6673-3-S1-S6. J Occup Med Toxicol. 2008. PMID: 18315837 Free PMC article. - Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.
Kish-Catalone TM, Lu W, Gallo RC, DeVico AL. Kish-Catalone TM, et al. Antimicrob Agents Chemother. 2006 Apr;50(4):1497-509. doi: 10.1128/AAC.50.4.1497-1509.2006. Antimicrob Agents Chemother. 2006. PMID: 16569870 Free PMC article. - Genetic Polymorphism at CCL5 Is Associated With Protection in Chagas' Heart Disease: Antagonistic Participation of CCR1+ and CCR5+ Cells in Chronic Chagasic Cardiomyopathy.
Batista AM, Alvarado-Arnez LE, Alves SM, Melo G, Pereira IR, Ruivo LAS, da Silva AA, Gibaldi D, da Silva TDESP, de Lorena VMB, de Melo AS, de Araújo Soares AK, Barros MDS, Costa VMA, Cardoso CC, Pacheco AG, Carrazzone C, Oliveira W Jr, Moraes MO, Lannes-Vieira J. Batista AM, et al. Front Immunol. 2018 Apr 11;9:615. doi: 10.3389/fimmu.2018.00615. eCollection 2018. Front Immunol. 2018. PMID: 29696014 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous